S
S.D. Ryder
Researcher at Nottingham University Hospitals NHS Trust
Publications - 28
Citations - 773
S.D. Ryder is an academic researcher from Nottingham University Hospitals NHS Trust. The author has contributed to research in topics: Hepatitis C & Hepatitis. The author has an hindex of 10, co-authored 28 publications receiving 741 citations. Previous affiliations of S.D. Ryder include Queen's University.
Papers
More filters
Journal ArticleDOI
Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus.
TL;DR: Carriage of an apoE‐ϵ4 allele may be protective against liver damage caused by HCV, but not against damage due to various nonviral causes, yet another case in which apOE may determine the severity of a viral disease.
Journal ArticleDOI
Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection.
Anna M. Grabowska,Franziska Lechner,Paul Klenerman,Patrick J. Tighe,S.D. Ryder,Jonathan K. Ball,Brian J. Thomson,William L. Irving,R A Robins +8 more
TL;DR: The role of intrahepatic lymphocytes in the control of hepatitis C virus (HCV) infection and the pathology associated with it is not understood; most studies of the immunology of this infection use peripheral blood lymphocyte populations.
Journal ArticleDOI
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
Prakash Ramachandran,Andrew Fraser,Kosh Agarwal,Andrew Austin,Ashley Brown,Graham R. Foster,Ray Fox,Peter C. Hayes,Clifford Leen,Peter R. Mills,David Mutimer,S.D. Ryder,John F. Dillon +12 more
TL;DR: The nonstructural 3 serine protease inhibitors, boceprevir and telaprevir, represent the first in a new generation of directly acting antivirals against genotype 1 hepatitis C (HCV) infection that will increase the complexity of therapeutic regimens, the rates of side‐effects and costs.
Journal ArticleDOI
Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE).
Peter T. Donnan,David J. McLernon,John F. Dillon,S.D. Ryder,Paul Roderick,Frank Sullivan,William Rosenberg +6 more
TL;DR: High probability of liver disease was associated with being female, methadone use, alcohol dependency and deprivation, and retesting in primary care is the most cost-effective option.
Journal ArticleDOI
Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.
William L. Irving,Sherie Smith,Ruth Cater,Simon Pugh,Keith R. Neal,Carol Coupland,S.D. Ryder,Brian J. Thomson,M Pringle,M. Bicknell,Julia Hippisley-Cox +10 more
TL;DR: Less than 50% of newly diagnosed anti‐HCV positive patients are referred to an appropriate clinic for further investigation and management, reflecting both systems failure and patient choice.